O'Neill P A, Morton P B, Sharman P, Marlow H F, Stark R D
Br J Clin Pharmacol. 1984 Jan;17(1):37-41. doi: 10.1111/j.1365-2125.1984.tb04996.x.
The effects of ICI 118,587 and atenolol on the responses to submaximal exercise and on breathlessness were studied in six healthy subjects. Atenolol reduced heart rate at rest and during exercise whereas ICI 118,587 increased resting heart rate but caused a small reduction in the highest heart rate achieved during exercise. Neither ICI 118,587 nor atenolol significantly changed minute ventilation or oxygen uptake either at rest or during exercise. There were no effects on bronchomotor tone. The assessment of breathlessness was validated for the subjects participating in the study. Atenolol increased the intensity of breathlessness in relation either to ventilation or to oxygen uptake. This effect was not secondary to a change in bronchomotor tone but was possibly related to changes in pulmonary haemodynamics. On the other hand, the relationships of breathlessness to ventilation or to oxygen uptake were unchanged by ICI 118,587. The effects of ICI 118,587 on exercise tolerance and dyspnoea in patients with impaired cardiac function should now be determined.
在六名健康受试者中研究了ICI 118,587和阿替洛尔对次最大运动反应及呼吸困难的影响。阿替洛尔可降低静息及运动时的心率,而ICI 118,587可提高静息心率,但使运动时达到的最高心率略有降低。ICI 118,587和阿替洛尔在静息或运动时均未显著改变分钟通气量或摄氧量。二者对支气管运动张力均无影响。对参与研究的受试者进行的呼吸困难评估是有效的。阿替洛尔会使与通气或摄氧量相关的呼吸困难强度增加。这种效应并非继发于支气管运动张力的改变,而可能与肺血流动力学变化有关。另一方面,ICI 118,587并未改变呼吸困难与通气或摄氧量之间的关系。现在应确定ICI 118,587对心功能受损患者运动耐力和呼吸困难的影响。